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were done to evaluate memory (Morris water maze and elevated 
plus maze task), exploratory behavior and anxiety (Open field test) 
and locomotion (actophotometer). The rats were sacrificed on day 
43 after the last behavioral test. Markers for cellular oxidative stress, 
mitochondrial oxidative parameters, acetylcholine esterase activity, 
and aluminum concentration in the brain tissue were assessed.
Results: Chronic aluminium chloride treatment caused cognitive 
dysfunction (as shown by behavioral tasks) and mitochondrial 
and cellular oxidative damage compared with the vehicle-treated 
control group. Besides, aluminium chloride treatment significantly 
increased acetyl cholinesterase activity and aluminum concentration 
in the brain compared with control. Coadministration of 4-ME sig-
nificantly improved cognitive performance and attenuated cellular 
and mitochondrial oxidative damage, acetyl cholinesterase activity 
and aluminum concentration in aluminium-treated rats. Only 4-ME 
treatment for 42 days did not alter the studied parameters in rats.
Conclusion: Results of the study demonstrate neuroprotective poten-
tial of 4-ME against aluminium chloride–induced neurodegeneration. 
Thus, 4-ME can be a promising candidate in the management of 
Alzheimer’s disease.
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Introduction: Studies have suggested neurotoxic effects of amyloid 
β protein and oxidative stress in Alzheimer’s disease. In the present 
study, we have analyzed the effect of a diet rich in figs for 1 year on 
behavior abnormalities in AppSw 2576 AD transgenic mouse model.
Patients (or Materials) and Methods: The experimental groups of 
APP-transgenic mice from the age of 4 months were fed custom-mix 
diets (pellets) containing 4% figs. These experimental and control mice 
behavior status were examined every 3 months for a period of 1 year 
by Morris water maze test (for spatial memory and learning ability), 
T maze test (for position discrimination learning ability), rota rod test 
(for psychomotor coordination), elevated plus maze test and open field 
(for anxiety-related behavior), and open field test to analyze the effect 
of fig-rich diet rich on memory, anxiety, and learning skills.
Results: APPsw/Tg2576 mice fed with the control diet showed a 
trend of memory deficit, anxiety-related behavior, and severe impair-
ment in spatial learning ability, position discrimination learning abil-
ity and motor coordination compared with the wild-type mice on the 
same diet. The fig-rich diet fed AD mice showed significant behavior 
improvement when compared with AD Tg mice.
Conclusion: Our results suggest that long term supplementation of 
fig in the diet might have the beneficial effect in reducing the risk, 
delaying the onset or slowing the progression of Alzheimer’s disease 
and also our results suggest that further studies are needed to validate 
and determine the mechanism of action of these fruits against AD.
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Introduction: To determine the prevalence of drug-induced long QT 
at admission to a public psychiatric hospital and document associated 
factors in a cross-sectional approach.
Patients (or Materials) and Methods: All ECG recordings over a 
5-year period were reviewed for drug-induced long QT (QTc ≥ 500 
ms; certain or probable drug imputability) and associated conditions. 
Patients with drug-induced long QT (n = 62) were compared with a 
sample of patients with normal ECG (n = 143).
Results: Among 6790 inpatients, 27.3% had abnormal ECG, 1.6% 
had long QT, and 0.9% were detected as drug-induced long QT 
cases. Sudden cardiac death was recorded in 5 patients and torsades 
de pointes in 7 other patients. Drug-induced long QT patients had 
significantly higher frequencies of hypokalemia (19.4% vs 5.6%; P = 
0.004), hepatitis C virus infection (41.9% vs 9.8%; P < 0.001), HIV 
infection (24.2% vs 6.3%; P = 0.001), and abnormal T-wave mor-
phology (35.5% vs 15.4%; P = 0.003). Haloperidol, sertindole, clo-
tiapine, phenothiazines, fluoxetine, (es-) citalopram, and methadone 
were significantly more frequent in drug-induced long QT patients. 
After adjustment for hypokalemia, hepatitis C virus infection, HIV 
infection, and abnormal T-wave morphology, effects of haloperidol, 
clotiapine, phenothiazines, and (es-)citalopram remained statistically 
significant. Receiver operating characteristic curve analysis based on 
the number of endorsed factors per patient indicated that 85.5% of 
drug-induced long QT patients had ≥ 2 factors, whereas 81.1% of 
normal ECG patients had < 2 factors.
Conclusion: Drug-induced long QT and arrhythmia propensity sub-
stantially increase when specific psychotropic drugs are administered 
to patients with hypokalemia, abnormal T-wave morphology, hepa-
titis C virus infection, and HIV infection.
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Introduction: Hepatic metabolism of clomipramine (C) consists of 
demethylation into the active metabolite desmethylclomipramine 
(DC) by CYP2C19 and CYP3A4, and hydroxylation of the par-
ent drug and the metabolite catalyzed by CYP2D6. CYP2D,6 and 
CYP2C19 are characterized by genetically determined polymor-
phisms. The influence of CYP2D6 and CYP2C19 polymorphisms on 
C and DC plasma concentrations and on occurrence of adverse effects 
is well described, but its role on clinical outcome is more anecdotal.
Patients (or Materials) and Methods: We report the case of a 40-year-
old woman with severe recurrent depressive disorder, history of 
several suicide attempts, borderline personality disorder, and fibro-
myalgia, who was admitted in Geneva Psychiatric Hospital during 6 
months for her fourth suicide attempt. Oral treatments with dulox-
etine (30 mg/d), escitalopram (30 mg/d), venlafaxine (225 mg/d), and 
mirtazapine (30 mg/d) were successively tried but were considered 
ineffective. A significant improvement, observed by the caregivers 
and the patient herself, was eventually obtained with intravenous (IV) 
clomipramine (50 mg/d). The patient returned home with oral clomi-
pramine (112.5 mg/d), olanzapine (5 mg/d), flurazepam (15 mg/d), 
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clorazepate (20mg 2× /d), and pregabalin (100 mg 3× /d). Because of 
resurgence of severe anxio-depressive symptoms, without any change 
of the treatment, the patient was readmitted 2 months later. Despite 
increasing the dose of clomipramine up to 225 mg/d, there was no 
clinical improvement, and the patient finally attempted to her life by 
abusing drugs. She then improved after 2 weeks on clomipramine 
IV (50 mg/d). Compliance was estimated good and no pharmacoki-
netic interactions with the rest of the treatment were found. C and 
DC plasma levels were measured, and CYP2D6/CYP2C19 genotype 
analyzed.
Results: The plasma levels of C and DC are given in the table 
below. Measures were done at the steady state and at trough con-
centration for IV treatment and 10 hours after the last dose for oral 
treatment.
Clomipramine bioavailability, 50%.
The CYP2D6 genotyping was CYP2D6 *1/*2xN, compatible 
with an ultrarapid metabolizer. The CYP2C19 genotyping was 
CYP2C19*1/*1, compatible with an extensive metabolizer.
Conclusion: The lack of clinical effect of oral clomipramine after a 
dramatic response to IV administration and the low per os plasma 
levels of clomipramine and its active metabolite, desmethylclo-
mipramine, suggested a rapid phenotype for CYP2D6. This was 
confirmed by genotyping. This case stresses the value of genotype 
determination to assess treatment failures in a population of patient 
wherein lack of compliance is often mentioned.
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Introduction: Dravet syndrome (DS) is a rare pediatric epilepsy of 
early life onset characterized by pharmacoresistant hemi- or gen-
eralized (tonic)-clonic seizures and severe cognitive prognosis. The 
voltage-gated sodium channel SCN1A gene is mutated in 85% of 
the patients. Transgenic mice models of DS suggest that the mutation 
specifically involves GABAergic interneurons and leads to selective 
loss of sodium current affecting their firing properties. However, the 
mechanisms leading from interictal activity to seizure generation and 
the subtype of interneurons involved are not known. Computational 
modeling of neuronal network is currently used to analyze these mech-
anisms. The inconsistency of firing rate in GABAergic interneurons 
can be used as a starting point to build a computational model of DS.
Objectives: To find parameters and connections in the model that 
reproduce EEG patterns of DS patients.
Patients (or Materials) and Methods: We first made a quantitative 
and qualitative analysis of EEG recorded in DS patients during inter-
ictal, preictal, and ictal periods. We next used a lumped-parameter 
approach (mean-field model) lying at the level of neuronal popu-
lation and able to represent the generation of spontaneous EEG. 
This computational model includes 1 subpopulation of pyramidal 
cells and 2 subpopulations of interneurons (mediating fast and slow 
GABAergic currents).
Results: EEG signals were characterized by slow background 
activity (1–4 Hz), multifocal interictal epileptic spikes and, as far 
as hemi-clonic seizures were concerned, by fast oscillations at the 
onset of seizures. To mimic the effect of a SCN1A mutation, the fir-
ing rate of GABAergic current was modified in slow interneurons. 
Preliminary results show that appropriate alterations in the strengths 
of GABAergic and glutamatergic connections, and in the amplitudes 
of average EPSPs/IPSPs in the model successfully lead to slow back-
ground activity (1–4 Hz), generation of interictal epileptic spikes, 
and fast onset activity and seizure-like activity.
Conclusion: Our computational modeling of DS is therefore promis-
ing. Further optimization is needed for reproducing all the features 
of the real EEG from patients and identifying the key parameters of 
specific EEG patterns.
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Introduction: Several anticancer medicines evoke sensory adverse 
events, collectively referred to as chemotherapy-induced peripheral 
neuropathy (CIPN), which are represented by sensory symptoms. 
No effective therapy is currently available to treat or prevent CIPN, 
most likely because the underlying mechanisms are poorly under-
stood. A host of hypotheses has been proposed to explain CIPN, 
but nonetheless no unified mechanism that may reconcile results of 
clinical investigation and findings obtained in experimental animals 
has been advanced so far. Chemotherapeutic drugs, which produce 
CIPN, are known to increase oxidative stress and reactive oxygen, 
nitrogen, or carbonyl species (ROS, RNS, and RCS, respectively) 
and treatment with antioxidant substances has been shown to reduce 
sensory hypersensitivity in experimental animals and to exhibit some 
degree of protection in patients with CIPN. The transient potential 
receptor ankyrin 1 (TRPA1) is a nonselective cation channel, co-
expressed with TRP vanilloid 1 (TRPV1) in a subset of C-fiber noci-
ceptors, where it functions as a multimodal sensor to noxious stimuli. 
TRPA1 shows a unique sensitivity for an unprecedented number of 
endogenous reactive molecules produced at sites of tissue injury or 
inflammation, which include ROS, RNS and RCS. Bortezomib is 
a proteasome inhibitor used indifferent types of cancer. CIPN has 
Table. Doses and plasma levels.
Posology (mg/d)
Route of administration 150 50
oral intravenous
C (micromol/l) 0.3-0.8 0.17 0.28
DC (micromol/l) 0.14 0.27
C + DC (micromol/l) 0.8-1.6 0.31 0.55
